205 related articles for article (PubMed ID: 37276043)
21. Fezolinetant.
Am J Health Syst Pharm; 2023 Aug; 80(17):1113-1114. PubMed ID: 37382493
[No Abstract] [Full Text] [Related]
22. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107
[No Abstract] [Full Text] [Related]
23. Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
Onge ES; Phillips B; Miller L
J Pharm Technol; 2023 Dec; 39(6):291-297. PubMed ID: 37974591
[No Abstract] [Full Text] [Related]
24. KarXT for schizophrenia-effectiveness and value: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
McKenna A; Tice JA; Whittington MD; Wright AC; Richardson M; Raymond FR; Pearson SD; Rind DM; Agboola F
J Manag Care Spec Pharm; 2024 Jun; 30(6):624-628. PubMed ID: 38824622
[No Abstract] [Full Text] [Related]
25. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
26. Fezolinetant findings can fuel future instrumentation inquiries.
Carpenter JS
Menopause; 2020 Dec; 27(12):1347. PubMed ID: 33048862
[No Abstract] [Full Text] [Related]
27. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
[TBL] [Abstract][Full Text] [Related]
28. Totality of evidence refutes neoplasm risk with fezolinetant.
Neal-Perry G; Santoro N; Cano A; Nappi RE; Shapiro M; Ottery FD
Lancet; 2024 May; 403(10440):1987-1988. PubMed ID: 38762322
[No Abstract] [Full Text] [Related]
29. Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2024 May; 403(10440):1988. PubMed ID: 38762323
[No Abstract] [Full Text] [Related]
30. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
Nikitin D; Makam AN; Suh K; McKenna A; Carlson JJ; Richardson M; Rind DM; Pearson SD
J Manag Care Spec Pharm; 2023 Feb; 29(2):216-221. PubMed ID: 36705279
[No Abstract] [Full Text] [Related]
31. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
DePree B
touchREV Endocrinol; 2023 Nov; 19(2):69-72. PubMed ID: 38187079
[TBL] [Abstract][Full Text] [Related]
32. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes.
Reame NK
Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443
[No Abstract] [Full Text] [Related]
33. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
34. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Rani P; Zehra D; Mansoor M; Rani P
Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
[TBL] [Abstract][Full Text] [Related]
35. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
Langley PC
Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
[TBL] [Abstract][Full Text] [Related]
37. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact.
Yamamoto K; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505
[TBL] [Abstract][Full Text] [Related]
38. The 2023 nonhormone therapy position statement of The North American Menopause Society.
“The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2023 Jun; 30(6):573-590. PubMed ID: 37252752
[TBL] [Abstract][Full Text] [Related]
39. A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Otuonye IS; Banken R; Kumar VM; Pearson SD
J Manag Care Spec Pharm; 2019 Jun; 25(6):630-634. PubMed ID: 31134864
[TBL] [Abstract][Full Text] [Related]
40. "Veozah (Fezolinetant): A Promising Non-Hormonal Treatment for Vasomotor Symptoms in Menopause".
Shaukat A; Mujeeb A; Shahnoor S; Nasser N; Khan AM
Health Sci Rep; 2023 Oct; 6(10):e1610. PubMed ID: 37808928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]